Takeda Pharmaceutical Reportedly Found Liable in Constipation Drug Antitrust Case

MT Newswires Live05-19

Takeda Pharmaceutical (TAK) was found liable by a US jury for using an anticompetitive agreement to delay a generic version of its constipation drug Amitiza, according to media reports Monday.

The verdict, delivered in the US District Court for the District of Massachusetts, stemmed from claims that Takeda and former partner Sucampo Pharmaceuticals entered into a "pay-for-delay" settlement with Par Pharmaceutical that postponed generic competition for years, Reuters reported.

Takeda Pharmaceutical said damages awarded to wholesaler and retailer plaintiffs are subject to automatic trebling under US antitrust law upon entry of judgment.

The company said it plans to appeal the ruling and believes the trial included both legal and evidentiary errors.

"We remain firm in our conviction that the plaintiffs' case lacks merit, and we will vigorously pursue post-trial motions and an appeal," the company said in a statement.

Takeda Pharmaceutical said the jury verdict will not have any impact on its 2025 full year financial results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636883147?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 17:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636883147","market":"sg","top_or_hot":-1,"title":"Takeda Pharmaceutical Reportedly Found Liable in Constipation Drug Antitrust Case","media":"MT Newswires Live","content":"<html><body><p> Takeda Pharmaceutical (TAK) was found liable by a US jury for using an anticompetitive agreement to delay a generic version of its constipation drug Amitiza, according to media reports Monday.</p><p>The verdict, delivered in the US District Court for the District of Massachusetts, stemmed from claims that Takeda and former partner <a href=\"https://laohu8.com/S/SCMP\">Sucampo Pharmaceuticals</a> entered into a \"pay-for-delay\" settlement with Par Pharmaceutical that postponed generic competition for years, Reuters reported.</p><p>Takeda Pharmaceutical said damages awarded to wholesaler and retailer plaintiffs are subject to automatic trebling under US antitrust law upon entry of judgment.</p><p>The company said it plans to appeal the ruling and believes the trial included both legal and evidentiary errors.</p><p>\"We remain firm in our conviction that the plaintiffs' case lacks merit, and we will vigorously pursue post-trial motions and an appeal,\" the company said in a statement.</p><p>Takeda Pharmaceutical said the jury verdict will not have any impact on its 2025 full year financial results.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Pharmaceutical Reportedly Found Liable in Constipation Drug Antitrust Case</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Pharmaceutical Reportedly Found Liable in Constipation Drug Antitrust Case\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-19 17:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Takeda Pharmaceutical (TAK) was found liable by a US jury for using an anticompetitive agreement to delay a generic version of its constipation drug Amitiza, according to media reports Monday.</p><p>The verdict, delivered in the US District Court for the District of Massachusetts, stemmed from claims that Takeda and former partner <a href=\"https://laohu8.com/S/SCMP\">Sucampo Pharmaceuticals</a> entered into a \"pay-for-delay\" settlement with Par Pharmaceutical that postponed generic competition for years, Reuters reported.</p><p>Takeda Pharmaceutical said damages awarded to wholesaler and retailer plaintiffs are subject to automatic trebling under US antitrust law upon entry of judgment.</p><p>The company said it plans to appeal the ruling and believes the trial included both legal and evidentiary errors.</p><p>\"We remain firm in our conviction that the plaintiffs' case lacks merit, and we will vigorously pursue post-trial motions and an appeal,\" the company said in a statement.</p><p>Takeda Pharmaceutical said the jury verdict will not have any impact on its 2025 full year financial results.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TAK","symbol_name":"武田制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2636883147","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636883147","pubTimestamp":1779181993,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Takeda Pharmaceutical  was found liable by a US jury for using an anticompetitive agreement to delay a generic version of its constipation drug Amitiza, according to media reports Monday.The verdict, delivered in the US District Court for the District of Massachusetts, stemmed from claims that Takeda and former partner Sucampo Pharmaceuticals entered into a \"pay-for-delay\" settlement with Par Pharmaceutical that postponed generic competition for years, Reuters reported.Takeda Pharmaceutical said damages awarded to wholesaler and retailer plaintiffs are subject to automatic trebling under US antitrust law upon entry of judgment.The company said it plans to appeal the ruling and believes the trial included both legal and evidentiary errors.\"We remain firm in our conviction that the plaintiffs' case lacks merit, and we will vigorously pursue post-trial motions and an appeal,\" the company said in a statement.Takeda Pharmaceutical said the jury verdict will not have any impact on its 2025 f","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TAK":"武田制药","BK4007":"制药"},"translate_title":"据报道，武田制药在便秘药物反垄断案中被判负有责任","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":1},"content_text":"Takeda Pharmaceutical (TAK) was found liable by a US jury for using an anticompetitive agreement to delay a generic version of its constipation drug Amitiza, according to media reports Monday.The verdict, delivered in the US District Court for the District of Massachusetts, stemmed from claims that Takeda and former partner Sucampo Pharmaceuticals entered into a \"pay-for-delay\" settlement with Par Pharmaceutical that postponed generic competition for years, Reuters reported.Takeda Pharmaceutical said damages awarded to wholesaler and retailer plaintiffs are subject to automatic trebling under US antitrust law upon entry of judgment.The company said it plans to appeal the ruling and believes the trial included both legal and evidentiary errors.\"We remain firm in our conviction that the plaintiffs' case lacks merit, and we will vigorously pursue post-trial motions and an appeal,\" the company said in a statement.Takeda Pharmaceutical said the jury verdict will not have any impact on its 2025 full year financial results.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636883147","isCrawlerRequest":true}